LuciPazo — Pazopanib 200 mg, 120 pcs, Lucius

LuciPazo — Pazopanib Tablets 200 mg, 120 Tablets

Product code: 519

11622₴ 12650₴ -8% On order · from 10 days
1
Active ingredient
Dosage
200 mg
Dosage form Tablets
Tablets per pack 120

LuciPazo is a targeted antineoplastic agent belonging to the multi-kinase inhibitor class, indicated for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. The active pharmaceutical ingredient is pazopanib at a strength of 200 mg supplied as film-coated oral tablets (Pazopanib Tablets 200 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Pazopanib is a potent oral selective inhibitor of receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-alpha and beta), and stem cell factor receptor (c-Kit). Blockade of these kinases suppresses angiogenesis (the formation of new blood vessels supplying the tumor), reduces tumor blood supply, and inhibits tumor cell proliferation.

Supplied in a package containing 120 tablets of 200 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciPazo 200 mg:

  • ✅ Multi-Targeted Anti-Angiogenic Action: Blockade of VEGFR, PDGFR, and c-Kit to deprive tumors of blood supply.
  • ✅ Proven Efficacy: High therapeutic effectiveness in renal cell carcinoma and soft tissue sarcomas.
  • ✅ Convenient Oral Dosing: Taken orally once daily on an empty stomach.
  • ✅ Optimal Strength: 200 mg tablets allow flexible dose titration and adjustment.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Votrient).

LuciPazo is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Pazopanib (as pazopanib hydrochloride) — 200 mg (equivalent to 200 mg pazopanib).
  • Excipients: Microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate. Coating: hypromellose, macrogol, titanium dioxide, iron oxide yellow.

Packaging and Presentation: Film-coated tablets, 200 mg strength. Each package contains 120 tablets along with prescribing information. Labeled with LuciPazo (Pazopanib Tablets 200 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Pazopanib is a synthetic receptor tyrosine kinase (RTK) inhibitor. It suppresses the activity of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha, PDGFR-beta, and c-Kit, which are involved in neoangiogenesis, tumor growth, and metastasis. Inhibition of these targets leads to a decrease in tumor vasculature, tumor tissue ischemia, and delayed disease progression.

Pharmacokinetics:

  • Absorption: Following oral administration, pazopanib absorption is relatively slow; peak plasma concentration (Tmax) is achieved within approximately 2 to 4 hours. Food intake significantly increases drug bioavailability (therefore administration on an empty stomach is recommended).
  • Distribution: Human plasma protein binding is very high (exceeding 99%).
  • Metabolism: Extensively metabolized in the liver, primarily via CYP3A4 enzyme of the cytochrome P450 system, with minor contributions from CYP1A2 and CYP2C8.
  • Elimination: Excreted predominantly via feces (approx. 6% as unchanged drug and metabolites) and renally (less than 4%). Terminal elimination half-life (T1/2) averages approximately 30.9 hours.

LuciPazo is indicated in adult patients for:

  • Renal Cell Carcinoma: Treatment of adult patients with advanced renal cell carcinoma, as well as patients who have received prior cytokine therapy.
  • Soft Tissue Sarcomas: Treatment of adult patients with advanced soft tissue sarcomas who have received prior chemotherapy (including anthracycline-based therapy).

LuciPazo is administered orally once daily every day at approximately the same time.

Dosing Regimen:
The recommended standard dose is 800 mg (four 200 mg tablets) once daily. Continue treatment until disease progression or unacceptable toxicity occurs.

Administration Guidelines:
Tablets should be taken on an empty stomach (at least 1 hour before or 2 hours after food) with water. Tablets must be swallowed whole; do not break, crush, or chew due to pharmacokinetic alterations. If a dose is missed, do not take it if less than 12 hours remain before the next scheduled dose.

Administration of LuciPazo is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to pazopanib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic Impairment: Pronounced liver dysfunction (Child-Pugh Class C).

Pazopanib is metabolized primarily via CYP3A4:

  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Significantly elevate pazopanib plasma concentrations and toxicity risks (avoid concurrent use or reduce dose).
  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease pazopanib blood concentrations and reduce antitumor efficacy (avoid concurrent use).
  • Gastric Acid-Lowering Agents (proton pump inhibitors): May impair pazopanib absorption.

Pregnancy:
LuciPazo is contraindicated during pregnancy. Based on its mechanism of action, pazopanib may cause severe developmental birth defects and embryotoxicity. Females of reproductive potential and male partners must utilize effective reliable contraception during treatment and for at least 2 months following the final dose.

Lactation:
Excretion of pazopanib into human breast milk is unstudied, though potential risk to the child cannot be ruled out. Breastfeeding must be discontinued during treatment and for 2 weeks post-therapy.

The most frequent and clinically significant adverse reactions include:

  • Cardiovascular System: Arterial hypertension (a very common adverse event requiring continuous blood pressure monitoring), thromboembolic events.
  • Hepatic Abnormalities: Elevations in liver transaminases (ALT, AST) and bilirubin levels (routine laboratory monitoring required).
  • Gastrointestinal Tract: Diarrhea, nausea, vomiting, abdominal pain, dysgeusia, stomatitis.
  • Skin and Hair: Hypopigmentation of skin and hair (depigmentation), rash, alopecia.
  • General Disorders: Fatigue, asthenia, headache, weight decrease.

Symptoms:
Specific acute overdose symptoms of pazopanib are unestablished. Administration at high doses (up to 2000 mg) resulted in severe fatigue and arterial hypertension.

Treatment:
No specific antidote exists. In case of overdose, withhold treatment and initiate supportive and symptomatic care under rigorous medical observation.

Storage Requirements for LuciPazo 200 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciPazo 200 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Pazopanib Tablets 200 mg, and 120 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00